{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:22:15Z","timestamp":1785252135699,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaut.2024.103248","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T10:40:27Z","timestamp":1716633627000},"page":"103248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study"],"prefix":"10.1016","volume":"147","author":[{"given":"Marie","family":"Solignac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Fouillet-Desjonqueres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Duquesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Perrine","family":"Foray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Zekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-5332","authenticated-orcid":false,"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103248_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40744-016-0040-4","article-title":"Juvenile idiopathic arthritis: diagnosis and treatment","volume":"3","author":"Giancane","year":"2016","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2024.103248_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","article-title":"Current and future perspectives in the management of juvenile idiopathic arthritis","volume":"2","author":"Ruperto","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jaut.2024.103248_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"PRCSG Advisory Council and the CARRA registry investigators, new medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103248_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2024.103248_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103248_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103248_bib7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.jaut.2024.103248_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103248_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an Outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaut.2024.103248_bib11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain investigators, tofacitinib as Induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"COMFORT-I investigators, Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jaut.2024.103248_bib13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Paediatric rheumatology International trials Organisation (PRINTO) and pediatric rheumatology Collaborative study group (PRCSG), tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2024.103248_bib14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib15","doi-asserted-by":"crossref","first-page":"E7767","DOI":"10.3390\/ijms21207767","article-title":"Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors","volume":"21","author":"Pin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2024.103248_bib16","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103248_bib17","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103248_bib18","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","author":"Kim","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103248_bib19","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103248_bib20","article-title":"Janus kinase inhibitors in the treatment of type I interferonopathies: a case series from a single center in China","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103248_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single Centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaut.2024.103248_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40348-018-0085-2","article-title":"The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases","volume":"5","author":"Holzinger","year":"2018","journal-title":"Mol Cell Pediatr"},{"key":"10.1016\/j.jaut.2024.103248_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103248_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5863\/1551-6776-20.4.316","article-title":"Unlicensed and off-label drug Use in children before and after pediatric Governmental Initiatives","volume":"20","author":"Corny","year":"2015","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"key":"10.1016\/j.jaut.2024.103248_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2024.103248_bib26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label Pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103248_bib27","first-page":"443","article-title":"Treatment of refractory anti-NXP2 and anti-TIF1\u03b3 dermatomyositis with tofacitinib","volume":"19","author":"Navarro-Navarro","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaut.2024.103248_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in Amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00296-020-04767-2","article-title":"Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review","volume":"41","author":"Kyriakou","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2024.103248_bib30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2024.103248_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: a systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2024.103248_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis","volume":"80","author":"Ding","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103248_bib33","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2024.103248_bib34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and Histologic Features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103248_bib35","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103248_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2024.103248_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Gene Immun."},{"key":"10.1016\/j.jaut.2024.103248_bib38","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle Stem cell Proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2024.103248_bib39","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2024.103248_bib40","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103248_bib41","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103248_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-018-0468-1","article-title":"Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus","volume":"12","author":"Petri","year":"2019","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.jaut.2024.103248_bib43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/acr2.11618","article-title":"Type 1 interferon-stimulated gene expression and disease activity in pediatric rheumatic diseases: No Composite scores needed?","volume":"5","author":"Weiden","year":"2023","journal-title":"ACR Open Rheumatology"},{"key":"10.1016\/j.jaut.2024.103248_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.930071","article-title":"Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: a systematic review","volume":"9","author":"Boyadzhieva","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib45","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/ard-2022-223815","article-title":"Baricitinib for juvenile idiopathic arthritis: a monocentric case series","volume":"82","author":"Maccora","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103248_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.jaut.2024.103248_bib47","series-title":"Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)","author":"Randomized","year":"2022"},{"key":"10.1016\/j.jaut.2024.103248_bib48","series-title":"Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthritis","year":"2022"},{"key":"10.1016\/j.jaut.2024.103248_bib49","author":"Pfizer"},{"key":"10.1016\/j.jaut.2024.103248_bib50","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103248_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165616","article-title":"Type I interferon signature and cycling lymphocytes in macrophage activation syndrome","volume":"133","author":"Huang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103248_bib52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2017.08.026","article-title":"The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy","volume":"141","author":"Cooles","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103248_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2024.103248_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103248_bib55","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40264-016-0430-0","article-title":"Benefit and Risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster","volume":"39","author":"Yamaoka","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.jaut.2024.103248_bib56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s13555-021-00517-9","article-title":"Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a Scoping review","volume":"11","author":"G\u00f3mez-Arias","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2024.103248_bib57","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2024.103248_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single Centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:30:51Z","timestamp":1720816251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":58,"alternative-id":["S0896841124000829"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103248","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103248"}}